Navigation Links
DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
Date:4/15/2008

Data shows non-invasive assay effectively identifies melanoma

LA JOLLA, Calif., April 15 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, will present data at the American Association of Cancer Research on its non-invasive assay that distinguishes melanoma from benign moles. The study entitled: "A Non-invasive Genomic Assay for the Detection of Melanoma in Suspicious Pigmented Nevi", shows that the assay has 100% sensitivity and 90.6% specificity. The biomarker based on 20 target genes is being developed as part of the company's proprietary molecular-based approach that uses its EGIR(TM) (Epidermal Genetic Information Retrieval) technology to identify melanoma at the earliest stages of disease. The late breaking abstract #LB-221 will be presented at Poster Session 19 on Tuesday, April 15.

DermTech's EGIR ("tape stripping") method is based on applying a custom adhesive strip to the skin's surface to obtain RNA and subsequently using gene expression profiling techniques to identify disease.

"Results of this study suggest that the malignant melanocyte, directly or indirectly, induces an alteration in stratum corneum gene expression," said Sherman Chang, PhD, Director of Molecular Biology, DermTech. "These findings pave the way for the development of an objective assay based on genomic data -- a major advance over today's subjective method of identifying disease."

Although melanoma accounts for more than 70% of skin cancer deaths, when detected early it is considered highly curable. In current clinical practice, the detection of melanoma is based upon visual clinical cues including the "ABCDE" criteria for pigmented nevi and results of optical imaging techniques, such as dermoscopy and con-focal microscopy. However, depending upon the setting, only 1 to 10% of lesions biopsied for suspicion of melanoma are positive upon histopathologic examination. Thus, there is a substantial need for a test that enhances the ease and accuracy of melanoma detection.

About DermTech:

Headquartered in La Jolla, California, DermTech International is focused on the development and validation of molecular tests using specimens obtained from the skin. The company's proprietary Epidermal Genetic Information Retrieval (EGIR(TM)) technology is in clinical studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of tracking treatment efficacy for a variety of dermatologic and other conditions, including the effects of drugs on skin at the molecular level in advance of observable clinical results. DermTech is actively pursuing research using EGIR and its applications in the areas of melanoma, prostate cancer and various skin disorders, such as psoriasis. For additional information visit http://www.dermtech.com

Contacts:

DermTech

George Schwartz

CEO

858.450.4222

For DermTech

Jennifer Larson

415.409.2729

jlarson@labfive.com


'/>"/>
SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
2. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Kline Study: Better Brushing Habits Boost European Oral Care Sales
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. NASA study will help stop stowaways to Mars
8. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
9. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... After several promising treatments in Panama using ... of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received his ... following FDA approval of a second application for a single patient, investigational new ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has ... in leading laboratories all over the globe. Their cute firefly logo has been ... awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. These ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... delegation at BIO 2016 in San Francisco. Located at booth number 7301, representatives ... to answer questions and discuss the Thai biotechnology and life sciences sector. ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... recently became double board-certified in surgery and surgery of the hand by the ... is no stranger to going above and beyond in his pursuit of providing ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
Breaking Biology News(10 mins):